At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CHRO Chromocell Therapeutics Corp
Closed 07-01 16:00:00 EDT
1.35
+0.00
0.00%
High1.35
Low1.35
Vol0.00
Open1.35
D1 Closing1.35
Amplitude0.00%
Mkt Cap8.75M
Tradable Cap3.39M
Total Shares6.49M
T/O253.52K
T/O Rate0.00%
Tradable Shares2.51M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Channel Therapeutics to Implement 10-for-1 Reverse Stock Split
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using Its Nav1.7 Inhibitor in Multiple Preclinical in Vivo Models
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.